Clinical Trials for PersonGen BioTherapeutics

Explore 12 clinical trials worldwide

Showing 1-12 of 12 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: PersonGen BioTherapeutics

Clinical Trials (12)

NCT07188610
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
PHASE2Not yet recruiting
100 participants
Started: Oct 1, 2025 · Completed: Oct 1, 2027
1 condition1 sponsor0 locations
NCT06982547
Clinical Study on the Treatment of Refractory Rheumatoid Arthritis With UTAA91 Injection
EARLY_PHASE1Not yet recruiting
24 participants
Started: Jun 30, 2025 · Completed: Jun 30, 2040
1 condition1 sponsor1 location
NCT06982534
Clinical Study on the Treatment of Systemic Sclerosis With UTAA91 Injection.
EARLY_PHASE1Not yet recruiting
24 participants
Started: Jun 30, 2025 · Completed: Jan 31, 2040
1 condition1 sponsor1 location
NCT06970951
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
EARLY_PHASE1Not yet recruiting
15 participants
Started: May 18, 2025 · Completed: Apr 30, 2027
5 conditions1 sponsor1 location
NCT06871644
Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases
NANot yet recruiting
18 participants
Started: Mar 18, 2025 · Completed: Mar 31, 2027
1 condition1 sponsor1 location
NCT06417398
Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
EARLY_PHASE1Not yet recruiting
10 participants
Started: May 14, 2024 · Completed: May 1, 2025
7 conditions1 sponsor0 locations
NCT06361745
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
NARecruiting
10 participants
Started: Apr 2, 2024 · Completed: Mar 1, 2025
5 conditions1 sponsor1 location
NCT06279026
UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma
NARecruiting
15 participants
Started: Apr 1, 2024 · Completed: Jul 1, 2027
1 condition2 sponsors1 location
NCT06092047
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.
EARLY_PHASE1Recruiting
10 participants
Started: Oct 1, 2023 · Completed: Apr 30, 2028
1 condition2 sponsors1 location
NCT05562024
TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma
PHASE1Recruiting
24 participants
Started: Dec 30, 2022 · Completed: Feb 18, 2039
1 condition3 sponsors2 locations
NCT05445011
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia
PHASE1Recruiting
12 participants
Started: Jun 14, 2022 · Completed: Jun 14, 2027
1 condition2 sponsors1 location
NCT05017883
TAA05 Cell Injection in the Treatment of Recurrent / Refractory Acute Myeloid Leukemia
NARecruiting
5 participants
Started: Jul 1, 2021 · Completed: Oct 31, 2025
2 conditions2 sponsors1 location